Morgan Stanley Innate Pharma Sa Transaction History

Morgan Stanley

$1.23 Trillion
Q1 2024

A detailed history of Morgan Stanley transactions in Innate Pharma Sa stock. As of the latest transaction made, Morgan Stanley holds 44,124 shares of IPHA stock, worth $90,895. This represents 0.0% of its overall portfolio holdings.

Number of Shares

44,124

Previous 46,354 4.81%

Holding current value

$90,895

Previous $129,000 1.55%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$2.37 - $2.93 $5,285 - $6,533	-2,230 Reduced 4.81%	44,124 $127,000
Q4 2023 Feb 13, 2024	BUY	$2.17 - $2.93 $3,038 - $4,102	1,400 Added 3.11%	46,354 $129,000
Q3 2023 Nov 15, 2023	SELL	$2.49 - $3.29 $5,216 - $6,892	-2,095 Reduced 4.45%	44,954 $113,000
Q2 2023 Aug 14, 2023	SELL	$2.78 - $3.5 $4,650 - $5,855	-1,673 Reduced 3.43%	47,049 $144,000
Q1 2023 May 15, 2023	SELL	$2.67 - $3.86 $1,722 - $2,489	-645 Reduced 1.31%	48,722 $138,000

Q4 2022 Feb 14, 2023	SELL	$1.9 - $3.73 $14,221 - $27,919	-7,485 Reduced 13.17%	49,367 $184,000
Q3 2022 Nov 14, 2022	BUY	$2.0 - $3.2 $20,508 - $32,812	10,254 Added 22.01%	56,852 $114,000
Q2 2022 Oct 27, 2022	BUY	$2.0 - $3.55 $3,288 - $5,836	1,644 Added 3.66%	46,598 $126,000
Q2 2022 Aug 15, 2022	BUY	$2.0 - $3.55 $3,288 - $5,836	1,644 Added 3.66%	46,598 $126,000
Q1 2022 Oct 27, 2022	SELL	$2.7 - $4.8 $4,438 - $7,891	-1,644 Reduced 3.53%	44,954 $151,000
Q1 2022 May 13, 2022	BUY	$2.7 - $4.8 $15,184 - $26,995	5,624 Added 14.3%	44,954 $151,000
Q4 2021 Feb 14, 2022	BUY	$4.34 - $6.06 $93,748 - $130,902	21,601 Added 121.84%	39,330 $180,000
Q3 2021 Nov 15, 2021	BUY	$3.04 - $8.1 $53,896 - $143,604	17,729 New	17,729 $109,000

Others Institutions Holding IPHA

# of Institutions

Shares Held

254K

Call Options Held

Put Options Held

View Full List

About Innate Pharma SA

Ticker IPHA
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 79,893,000
Market Cap $165M
Description
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and periphera...

More about IPHA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account